IGM Biosciences Acquisition Finalized, Shareholders Receive Payout

The publicly traded journey of IGM Biosciences has concluded. The biotechnology firm is no longer listed as an independent entity on the stock exchange following its acquisition by Concentra Biosciences, LLC. Shareholders are receiving a fixed cash payment for each share held, along with the potential for additional future compensation.

On July 1, 2025, an agreement was signed for the takeover. The board of directors at IGM Biosciences unanimously approved the offer from Concentra Biosciences. The deal was subsequently finalized in August 2025.

Under the terms, Concentra Biosciences paid a fixed sum of $1,247 for each common share. In addition to this upfront cash, equity holders were granted a Contingent Value Right (CVR). This financial instrument provides the right to potential extra payments, contingent on future cash and asset sales generated by the company.

Should investors sell immediately? Or is it worth buying IGM Biosciences?

Acquisition Summary:
* Acquiring Entity: Concentra Biosciences, LLC
* Agreement Date: July 1, 2025
* Closing Date: August 2025
* Fixed Payout Per Share: $1,247 in cash
* Additional Consideration: Contingent Value Right (CVR)

Transition to a Wholly-Owned Subsidiary

Effective August 14, 2025, IGM Biosciences now operates as a subsidiary of Concentra Biosciences. The company's stock has been delisted from public markets, rendering its former trading symbol inactive across financial data platforms. This acquisition marks the end of IGM Biosciences' status as a standalone public company. At the point of merger, the share value was fixed at the agreed-upon cash amount of $1,247.